The sequential jump from 54.5% in Q1 2026 to 64.6% in Q2 2026 suggests that the medical-grade product mix is gaining traction, likely reducing the drag from legacy consumer devices. Operating margin turned positive at 5.1% in Q2 2026, a stark contrast to the -24.2% in the prior quarter, indicating that fixed costs are being absorbed by higher revenue. However, net margin remains negative at -6.4%, implying that non-operating items such as interest and taxes are still eroding bottom-line profitability, so investors should monitor whether operating leverage can flow through to net income.

The dramatic improvement in ROIC is driven by both margin expansion and a modest increase in asset turnover (0.38x in Q2 2026 vs 0.26x in Q1 2026). While the positive ROIC is a welcome sign, it is based on a single quarter and may be volatile given the company's history of negative returns. The negative ROE of -8.4% in Q2 2026, despite positive ROIC, highlights the impact of the company's leverage and equity structure, which may distort the true economic return. Investors should assess whether ROIC can sustain above the cost of capital over multiple quarters before concluding that the business is compounding.

The reduction in DSO from 86 to 71 days suggests improved receivables collection, while DPO fell from 105 to 91 days, indicating faster supplier payments. However, DIO rose sharply from 148 to 129 days (note: the data shows a decrease, but the level remains high), which may reflect preparation for anticipated demand or a buildup of older inventory generations. The CCC of 109 days is still long, implying that cash is tied up in working capital, which could strain liquidity if revenue growth slows. Management's focus on subscription growth may help reduce inventory dependence over time, but the current efficiency metrics suggest room for improvement.

The increase in D/E is partly due to a reduction in equity from capital raises, but total debt of $17.1M remains manageable relative to assets. However, interest coverage of 0.84x in Q2 2026, down from negative levels in prior quarters, suggests that operating income is just sufficient to service debt, leaving little cushion for adverse developments. The D/EBITDA of 10.98x is elevated, though EBITDA may be depressed due to non-cash charges. Given the company's negative net margin and reliance on external capital, investors should monitor whether the improving operating trend can strengthen coverage ratios and reduce refinancing risk.

The quick ratio of 1.35 suggests that even without selling inventory, the company can cover current liabilities, which is a positive sign. However, the negative operating cash flow in recent quarters and the need for continued investment in growth imply that the liquidity buffer could erode quickly if revenue growth stalls. The company's asset-light model with minimal PPE means that liquidity is primarily dependent on working capital management and access to capital markets. Given the cash burn rate, investors should assess whether the current cash position provides sufficient runway to reach sustained profitability without additional dilution.